Patents by Inventor Karl T. Weber

Karl T. Weber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Medical uses of ultraviolet light
    Patent number: 7297155
    Abstract: A method of treating a patient having a condition selected from the group including hypertension, hypertensive crises, angina pectoris, chronic arthritis, erectile dysfunction, cerebral ischemia and chronic skin ulcers comprising the step of administering to the patient a therapeutically effective amount or dose, or series of amounts or doses, of ultraviolet light.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: November 20, 2007
    Inventors: E. William Rosenberg, Karl T. Weber, Robert M. Sayre, John C. Dowdy, James G. Shepherd
  • Use of aldosterone antagonists to inhibit myocardial fibrosis
    Publication number: 20020013303
    Abstract: This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
    Type: Application
    Filed: April 24, 2000
    Publication date: January 31, 2002
    Inventor: Karl T. Weber
  • Use of aldosterone antagonists to inhibit myocardial fibrosis
    Patent number: 6245755
    Abstract: This invention discloses a method of inhibiting aldosterone-mediated myocardial, perivascular and interstitial fibrosis using epoxymexrenone and other aldosterone antagonists.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: June 12, 2001
    Assignee: Curators of the Unversity of Missouri
    Inventor: Karl T. Weber
  • Oligmers which inhibit expression of collagen genes
    Patent number: 6156513
    Abstract: Oligomers which inhibit expression of a collagen gene are described. It is believed that each oligomer, when introduced into a cell, forms a transcription-inhibiting complex composed of the oligomer and the collagen-gene promoter region. The oligomer, preferably a phosphorothioate deoxyoligonucleotide or a ribonucleotide, preferably binds in the antiparallel orientation to the polypurine strand of a polypurine-polypyrimidine region of the promoter region of a mammalian .alpha.1(I) collagen gene.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: December 5, 2000
    Assignee: Ramareddy V. Guntaka
    Inventors: Ramareddy V. Guntaka, Karl T. Weber, Attilla Kovacs, Jagannadhachari Kandala
  • Use of aldosterone antagonists to inhibit myocardial fibrosis
    Patent number: 6150347
    Abstract: This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: November 21, 2000
    Assignee: The Curators of the University of Missouri
    Inventor: Karl T. Weber
  • Use of aldosterone antagonists to inhibit myocardial fibrosis
    Patent number: 6093708
    Abstract: This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: July 25, 2000
    Assignee: The Curators of the University of Missouri
    Inventor: Karl T. Weber
  • Use of aldosterone antagonists to inhibit myocardial fibrosis
    Patent number: 6008210
    Abstract: This invention discloses a method of inhibiting myocardial fibrosis by administering epoxymexrenone at a dosage which does not substantially increase sodium excretion by the body.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: December 28, 1999
    Inventor: Karl T. Weber
  • Use of aldosterone antagonists to inhibit myocardial fibrosis
    Patent number: 5668124
    Abstract: This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
    Type: Grant
    Filed: March 28, 1996
    Date of Patent: September 16, 1997
    Inventor: Karl T. Weber
  • Use of aldosterone antagonists to inhibit myocardial fibrosis
    Patent number: 5668125
    Abstract: This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
    Type: Grant
    Filed: December 28, 1995
    Date of Patent: September 16, 1997
    Inventor: Karl T. Weber
  • Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
    Patent number: 5529992
    Abstract: This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: June 25, 1996
    Assignee: Curators of the University of Missouri
    Inventor: Karl T. Weber